Keywords: |
protein kinase b; cancer chemotherapy; fatigue; diarrhea; drug safety; solid tumor; antineoplastic agents; neoplasms; pharmacodynamics; notch receptor; editorial; phosphatidylinositol 3 kinase; survivin; acute lymphoblastic leukemia; coughing; myc protein; receptors, notch; drug half life; cyclin d1; benzazepines; alzheimer disease; notch1 receptor; amyloid precursor protein secretases; sulfones; notch4 receptor; phase 1 clinical trial (topic); amyloid beta protein; mk 0752; n (6,7 dihydro 6 oxo 5h dibenz[b,d]azepin 7 yl) 2,2 dimethyl n' (2,2,3,3,3 pentafluoropropyl)propanediamide; propionic acids
|